Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Nanomedicine. 2013;8:2669-76. doi: 10.2147/IJN.S45821. Epub 2013 Jul 24.

In vitro evaluation of 5-aminolevulinic acid (ALA) loaded PLGA nanoparticles.

Author information

1
Shanghai Skin Disease Hospital, Shanghai, People's Republic of China.

Abstract

BACKGROUND:

5-Aminolevulinic acid (ALA) is a prodrug for topical photodynamic therapy. The effectiveness of topical ALA can be limited by its bioavailability. The aim of this study was to develop a novel ALA delivery approach using poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs).

METHODS:

A modified double emulsion solvent evaporation method was used to prepare ALA loaded PLGA NPs (ALA PLGA NPs). The characteristics, uptake, protoporphyrin IX fluorescence kinetics, and cytotoxicity of ALA PLGA NPs toward a human skin squamous cell carcinoma cell line were examined.

RESULTS:

The mean particle size of spherical ALA PLGA NPs was 65.6 nm±26 nm with a polydispersity index of 0.62. The encapsulation efficiency was 65.8%±7.2% and ALA loading capacity was 0.62%±0.27%. When ALA was dispersed in PLGA NPs, it turned into an amorphous phase. ALA PLGA NPs could be taken up by squamous cell carcinoma cells and localized in the cytoplasm. The protoporphyrin IX fluorescence kinetics and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay showed that ALA PLGA NPs were more effective than free ALA of the same concentration.

CONCLUSION:

PLGA NPs provide a promising ALA delivery strategy for topical ALA-photodynamic therapy of skin squamous cell carcinoma.

KEYWORDS:

5-Aminolevulinic acid (ALA); nanoparticles; photodynamic therapy (PDT); poly(lactic-co-glycolic acid) (PLGA); skin squamous cell carcinoma

PMID:
23926429
PMCID:
PMC3728265
DOI:
10.2147/IJN.S45821
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Support Center